News in Brief

PsychoGenics, Blue Oak partner to identify new treatments for brain disorders

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Natali_Mis)
(Image: Getty/Natali_Mis)
Blue Oak Pharmaceuticals, Inc. and PGI Drug Discovery LLC (PsychoGenics) have entered into a drug discovery partnership to optimize novel treatments for brain disorders and psychiatric conditions.

PsychoGenics is a Paramus, NJ-based preclinical contract research organization (CRO).

Per the agreement, PsychoGenics will provide access to its phenotypic discovery platforms. This includes its SmartCube system, the company’s a proprietary high throughput, high content, in vivo​ screening platform.

According to the CRO, its platforms combine in vivo​ behavioral knowledge with advances in robotics, computer vision, and bioinformatics to evaluate drug candidates.

We are confident that combining PGI’s deep behavioral profiling with Blue Oak’s privileged chemotypes and brain imaging biomarkers will yield the new therapies that have eluded the industry for several decades,​” said Tom Large, PhD., Blue Oak’s president and CEO in a press release.

Blue Oak and PsychoGenics have not responded to a request for comment.

Related topics: Clinical Development

Related news

Show more